| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLE |
Departments of Obstetrics and Gynecology and Cell Biology and Physiology (H.L.), Washington University School of Medicine, St. Louis, Missouri 63110; and Department of Molecular and Integrative Physiology (S.K.D), Ralph L. Smith Research Center, University of Kansas Medical Center, Kansas City, Kansas 66160
Address all correspondence and requests for reprints to: H. Lim, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri 63110. E-mail: limj{at}msnotes.wustl.edu; or S. K. Dey, Department of Molecular and Integrative Physiology, Ralph L. Smith Research Center, University of Kansas Medical Center, Kansas City, Kansas 66160. E-mail: sdey{at}kumc.edu.
Prostacylin (PGI2), one of the major prostaglandins, is derived from arachidonic acid by the action of the cyclooxygenase (COX) system coupled to PGI2 synthase (PGIS). The presence of the COX-2/PGIS at the nuclear and endoplasmic reticular membrane suggests differential signaling pathways of PGI2 actions involving both cell surface and nuclear receptors. Although the signaling of PGI2 via its cell surface receptor, prostacyclin receptor (IP), is well documented in vascular biology, its action via nuclear receptors in other physiological responses is gradually being more appreciated. Peroxisomal proliferator-activated receptors (PPARs), PPAR
, PPAR
, and PPAR
, though initially cloned as a family of orphan receptors, are now known for their ligand promiscuity. The ligands range from free fatty acids and their derivatives produced by the cyclooxygenase or lipoxygenase pathway to certain hypolipidemic drugs. The predisposition of PPARs to use a wide spectrum of ligands is well explained by their unusually large ligand-binding pocket. The promiscuous ligand usage by PPARs is also reflected by their involvement in various pathophysiological events. Several recent independent reports show that endogenously produced PGI2 indeed activates PPAR
in vivo, indicating that a novel signaling mechanism for this abundant eicosanoid is operative in certain systems. This review attempts to cover recent developments in nuclear actions of PGI2 in diverse biological functions.
This article has been cited by other articles:
![]() |
N. J. Skill, N. G. Theodorakis, Y. N. Wang, J. M. Wu, E. M. Redmond, and J. V. Sitzmann Role of cyclooxygenase isoforms in prostacyclin biosynthesis and murine prehepatic portal hypertension Am J Physiol Gastrointest Liver Physiol, November 1, 2008; 295(5): G953 - G964. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nemenoff, A. M. Meyer, T. M. Hudish, A. B. Mozer, A. Snee, S. Narumiya, R. S. Stearman, R. A. Winn, M. Weiser-Evans, M. W. Geraci, et al. Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator-Activated Receptor {gamma} Cancer Prevention Research, October 1, 2008; 1(5): 349 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. He, T. Lu, L. V. d'Uscio, C.-F. Lam, H.-C. Lee, and Z. S. Katusic Angiogenic Function of Prostacyclin Biosynthesis in Human Endothelial Progenitor Cells Circ. Res., July 3, 2008; 103(1): 80 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. C. Kengni, I. St-Louis, S. Parent, V. Leblanc, C. Shooner, and E. Asselin Regulation of prostaglandin D synthase and prostacyclin synthase in the endometrium of cyclic, pregnant, and pseudopregnant rats and their regulation by sex steroids J. Endocrinol., November 1, 2007; 195(2): 301 - 311. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jaffar, M. E. Ferrini, M. C. Buford, G. A. FitzGerald, and K. Roberts Prostaglandin I2-IP Signaling Blocks Allergic Pulmonary Inflammation by Preventing Recruitment of CD4+ Th2 Cells into the Airways in a Mouse Model of Asthma J. Immunol., November 1, 2007; 179(9): 6193 - 6203. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lin, C.-C. Hou, C.-F. Cheng, T.-H. Chiu, Y.-H. Hsu, Y.-M. Sue, T.-H. Chen, H.-H. Hou, Y.-C. Chao, T.-H. Cheng, et al. Peroxisomal Proliferator-Activated Receptor-{alpha} Protects Renal Tubular Cells from Doxorubicin-Induced Apoptosis Mol. Pharmacol., November 1, 2007; 72(5): 1238 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Freedman, E. Wang, S. Voiculescu, R. Patenia, R. L. Bassett Jr., M. Deavers, F. M. Marincola, P. Yang, and R. A. Newman Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer Clin. Cancer Res., October 1, 2007; 13(19): 5736 - 5744. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Eyster The membrane and lipids as integral participants in signal transduction: lipid signal transduction for the non-lipid biochemist Advan Physiol Educ, March 1, 2007; 31(1): 5 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Froment, F Gizard, D Defever, B Staels, J Dupont, and P Monget Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J. Endocrinol., May 1, 2006; 189(2): 199 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, J. D. Potter, and C. M. Ulrich Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 502 - 508. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Y. Ali, K. Egan, G. A. FitzGerald, B. Desvergne, W. Wahli, D. Bishop-Bailey, T. D. Warner, and J. A. Mitchell Role of Prostacyclin versus Peroxisome Proliferator-Activated Receptor beta Receptors in Prostacyclin Sensing by Lung Fibroblasts Am. J. Respir. Cell Mol. Biol., February 1, 2006; 34(2): 242 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nasrallah and R. L. Hebert Prostacyclin signaling in the kidney: implications for health and disease Am J Physiol Renal Physiol, August 1, 2005; 289(2): F235 - F246. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Di-Poi, C. Y. Ng, N. S. Tan, Z. Yang, B. A. Hemmings, B. Desvergne, L. Michalik, and W. Wahli Epithelium-Mesenchyme Interactions Control the Activity of Peroxisome Proliferator-Activated Receptor {beta}/{delta} during Hair Follicle Development Mol. Cell. Biol., March 1, 2005; 25(5): 1696 - 1712. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Korita, H. Itoh, N. Sagawa, S. Yura, M. Yoshida, K. Kakui, M. Takemura, and S. Fujii 17{beta}-Estradiol Up-Regulates Prostacyclin Production in Cultured Human Uterine Myometrial Cells Via Augmentation of Both Cyclooxygenase-1 and Prostacyclin Synthase Expression Reproductive Sciences, October 1, 2004; 11(7): 457 - 464. [Abstract] [PDF] |
||||
![]() |
R. Nasrallah and R. L. Hebert Reduced IP receptors in STZ-induced diabetic rat kidneys and high-glucose-treated mesangial cells Am J Physiol Renal Physiol, October 1, 2004; 287(4): F673 - F681. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sirois, K. Sayasith, K. A. Brown, A. E. Stock, N. Bouchard, and M. Dore Cyclooxygenase-2 and its role in ovulation: a 2004 account Hum. Reprod. Update, September 1, 2004; 10(5): 373 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Dey, H. Lim, S. K. Das, J. Reese, B. C. Paria, T. Daikoku, and H. Wang Molecular Cues to Implantation Endocr. Rev., June 1, 2004; 25(3): 341 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Lim, I. Moon, and K. Han Transcriptional Cofactors Exhibit Differential Preference toward Peroxisome Proliferator-Activated Receptors {alpha} and {delta} in Uterine Cells Endocrinology, June 1, 2004; 145(6): 2886 - 2895. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.D. Norata, E. Callegari, H. Inoue, and A.L. Catapano HDL3 Induces Cyclooxygenase-2 Expression and Prostacyclin Release in Human Endothelial Cells Via a p38 MAPK/CRE-Dependent Pathway: Effects on COX-2/PGI-Synthase Coupling Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 871 - 877. [Abstract] [Full Text] |
||||
![]() |
S Battersby, H O D Critchley, A J de Brum-Fernandes, and H N Jabbour Temporal expression and signalling of prostacyclin receptor in the human endometrium across the menstrual cycle Reproduction, January 1, 2004; 127(1): 79 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. E. Berry, R. Eykholt, R. J. A. Helliwell, R. S. Gilmour, M. D. Mitchell, and K. W. Marvin Peroxisome Proliferator-Activated Receptor Isoform Expression Changes in Human Gestational Tissues with Labor at Term Mol. Pharmacol., December 1, 2003; 64(6): 1586 - 1590. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |